Head-to-head evidence
Laromestrocel vs RB-ADSC
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Mesenchymal stem cell therapy · full Alzheimer's Disease pipeline
Laromestrocel · Lomecel-B
Developed by Longeveron (NASDAQ: LGVN)
NCT05233774 · Phase 2 · completed
This trial was randomized, blinded, and placebo-controlled, but it enrolled only 50 patients and was designed primarily to test safety rather than a clinical outcome; cognitive measures were assessed only as secondary endpoints. The safety objective was met, but the small size and safety-focused design mean this trial does not by itself demonstrate a clinical benefit.
RB-ADSC
Developed by Regeneration Biomedical, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2028 · NCT07373067 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Laromestrocel's landscape · RB-ADSC's landscape